D
Derek L. Buhl
Researcher at Pfizer
Publications - 32
Citations - 4616
Derek L. Buhl is an academic researcher from Pfizer. The author has contributed to research in topics: Hippocampus & Medicine. The author has an hindex of 17, co-authored 28 publications receiving 4112 citations. Previous affiliations of Derek L. Buhl include Massachusetts Institute of Technology & Rutgers University.
Papers
More filters
Journal ArticleDOI
Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation.
Patricio O'Donnell,Patricio O'Donnell,Francis M Dijkstra,Ugur Damar,Lei Quanhong,Annika A de Goede,Lin Xu,Andres Pascual-Leone,Derek L. Buhl,Rob Zuiker,Titia Q Ruijs,Jules A A C Heuberger,Paul MacMullin,Martin Lubell,Mahnaz Asgharnejad,Venkatesha Murthy,Alexander Rotenberg,Gabriel E. Jacobs,Laura Rosen +18 more
TL;DR: TAK-653 is a novel α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-positive allosteric modulator being developed as a potential therapeutic for major depressive disorder (MDD).
Journal ArticleDOI
Safety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects.
Wei Yin,Fahimeh Mamashli,Derek L. Buhl,Polyna Khudyakov,Dmitri Volfson,Ferenc Martenyi,Hakop Gevorkyan,Laura Rosen,Arthur A. Simen +8 more
TL;DR: In this article, TAK-071 was administered as single and multiple doses in a randomized, double-blind, placebo-controlled, parallel-group design in healthy volunteers alone and in combination with donepezil.
Journal ArticleDOI
Automated Sleep Stage Scoring Using k-Nearest Neighbors Classifier
Tamás Kiss,Stephen R. Morairty,Michael D. Schwartz,Thomas S. Kilduff,Derek L. Buhl,Dmitri Volfson +5 more
TL;DR: Given the evolutionary relatedness of mammalian species, sleep architecture and changes therein may provide reliable translational biomarkers for pharmacological engagement in proof-of-mechanism clinical studies.
Journal ArticleDOI
High reproducibility across sites in a pre-clinical study through a coordinated behavioural and pharmacological protocol
M. Arroyo Araujo,Radka Graf,Martine Maco,E. Van Dam,E. Schenker,Pim Drinkenburg,Bastijn Koopmans,S.F. de Boer,M. Cullum-Doyle,Lucas P. J. J. Noldus,Maarten Loos,W. Van Dommelen,W. Spooren,Barbara Biemans,Derek L. Buhl,Martien J H Kas +15 more
Journal ArticleDOI
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers
Marco Cecchi,Marie Adachi,A. Basile,Derek L. Buhl,Heramb Chadchankar,S. Christensen,E. Christian,Julie Doherty,Kalford C. Fadem,B. Farley,Mater Forman,Shiori Honda,Jason K. Johannesen,B. J. Kinon,Daniel Klamer,M.J. Marino,Christopher Missling,Patriot O′Donnell,Timothy Piser,Corey B. Puryear,Michael C. Quirk,M. Rotte,Crystian Sánchez,Jason M. Uslaner,Daniel C. Javitt,Richard S.E. Keefe,D.H. Mathalon,William Z. Potter,Douglas P. Walling,Larry Ereshefsky +29 more
TL;DR: In this article , a clinical study on healthy volunteers (HV) and patients with schizophrenia (SZ) that assessed test-retest, group differences, variance, and correlation with functional assessments for ERP and QEEG measures collected at clinical and commercial trial sites with standardized instrumentation and methods, and analyzed through an automated data analysis pipeline.